Cytosorbents Corporation (CTSO)
-OTC Markets 0.13 
0.00(3.60%) May 24, 3:22PM EDT
| Prev Close: | 0.13 |
|---|
| Open: | 0.12 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 0.50 |
|---|
| Beta: | 1.28 |
|---|
| Next Earnings Date: | 12-Aug-13 |
|---|
| Day's Range: | 0.12 - 0.13 |
|---|
| 52wk Range: | 0.09 - 0.18 |
|---|
| Volume: | 275,522 |
|---|
| Avg Vol (3m): | 331,991 |
|---|
| Market Cap: | 29.77M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.03 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Alliance Advisors Announces Sponsorship of Marcum MicroCap ConferenceGlobeNewswire(Wed, May 22)
- CYTOSORBENTS CORP FinancialsEDGAR Online Financials(Tue, May 21)
- Awareness-Building Efforts Bearing FruitZacks Small Cap Research(Fri, May 17)
- CytoSorbents Reports 2013 First Quarter Financial ResultsGlobeNewswire(Thu, May 16)
- CYTOSORBENTS CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 15)
- CYTOSORBENTS CORP Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Mon, May 13)
- Kathleen P. Bloch Appointed as Chief Financial Officer of CytoSorbentsGlobeNewswire(Mon, May 13)
- CytoSorbents Enters Into Exclusive Distribution Agreement for CytoSorb(R) With L.IN.C. Medical Systems in the United Kingdom and IrelandGlobeNewswire(Mon, May 6)
- CytoSorbents CEO Provides Exclusive Interview With medGadgetGlobeNewswire(Wed, May 1)
- CytoSorbents Appoints Christopher Cramer as Vice President of Business DevelopmentGlobeNewswire(Mon, Apr 15)
- CytoSorbents Awarded Additional Phase I Option on US Army SBIR Trauma ContractGlobeNewswire(Thu, Apr 11)
- CytoSorbents Announces Trauma Advisory BoardGlobeNewswire(Mon, Apr 8)
- Q4 Results / Interest In CytoSorb AcceleratingZacks Small Cap Research(Thu, Apr 4)
- CytoSorbents Provides Corporate Update and Reports 2012 Year End Financial ResultsGlobeNewswire(Wed, Apr 3)
- CYTOSORBENTS CORP Files SEC form 10-K, Annual ReportEDGAR Online(Wed, Apr 3)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 17.27 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.05 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.01 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
CytoSorbents Corporation, a development stage company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology.
View More